



FORM PTO-1449 (modified)

To: U.S. Department of Commerce

(PW FORM PAT-1449)

Patent and Trademark Office

Atty.

Dkt. No.

M#

Client Ref.

0280647

1992-30-0029CP1C2

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: ANDERSON et al.

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Date: May 27, 2004

Page

1

of

1

Examiner: Schwadron, R.

Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR						
	BR						
	CR						
	DR						
	ER						
	FR						
	GR						
	HR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR						
	JR						
	KR						
	LR						
	MR						
	NR						
	OR						
	PR						

OTHER

BS	QR	Idec Pharmaceuticals v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).
BS	RR	Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).
	SR	
	TR	
	UR	
	VR	
	WR	
	XR	
	YR	
	ZR	
	AAR	

Examiner

Date Considered:

3/31/2005

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

0280647

1992-30-0029CP1C2

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: ANDERSON et al.

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Examiner: Schwadron, R.

Group Art Unit: 1644

Date: March 18, 2004

Page 1

of

1

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	MS	AR 5,595,721	01/1997	KAMINSKI et al.	—	—	
		BR 5,439,665	08/1995	HANSEN et al.	—	—	
		CR RE 38,008	02/2003	ABRAMS et al.	—	—	
		DR 5,736,137	04/1998	ANDERSON et al.	—	—	
		ER 5,776,456	07/1998	ANDERSON et al.	—	—	
		FR 5,843,439	12/1998	ANDERSON et al.	—	—	
		GR 6,399,061	06/2002	ANDERSON et al.	—	—	
		HR 6,682,734	01/2004	ANDERSON et al.	—	—	

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR	WO 94/11026	05/1994	PCT	ANDERSON et al.		
	JR						
	KR						
	LR						
	MR						

OTHER

MS	NR	Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80:863-878.
	OR	Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16(8):881-87.
	PR	Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19," <i>J Immunol</i> , 1988, 141(12):4388-94.
	QR	
	RR	
	SR	
	TR	
	UR	

Examiner

Date Considered:

3/31/2005

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

M#

Client Ref.

0280647

1992-30-0029CP1C2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: ANDERSON *et al.*

Appln. No.: 09/911,703

Filing Date: July 25, 2001

Date: November 21, 2003

Page

1

of

1

Examiner: R. Schwadron

Group Art Unit: 1644

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
MS	AR	6,183,744 B1	02/2001	GOLDENBERG	—	—	
MS	BR	6,306,393 B1	10/2001	GOLDENBERG	—	—	
	CR						
	DR						
	ER						
	FR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	GR						
	HR						
	IR						
	JR						
	KR						
	LR						

OTHER

MS	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
	NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
	OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.
	PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36.
	QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, Abstract No. 1409.
	RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp.1696-1711.
	SR	
	TR	
	UR	
	VR	


Examiner

[Signature]

Date Considered:

3/31/2003

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Atty. Dkt. No.	M#	Client Ref.
	037003-0280647	1992-30-0029CP1C2

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Anderson, et al.	
Appln. No.: 09/911,703	
Filing Date: July 25, 2001	
Examiner: Scwadron, R.	Group Art Unit: 1644

Date: October 21, 2003 Page 1 of 3

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
MS	AR 5,500,362	03/1996	Robinson, et al.	435	7.23	
MS	BR 5,648,267	07/1997	Reff	435	320.1	
	CR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclos	No
MS	DR	0 125 023 A1	11/1984	EP	Cabilly, et al.				
	ER	0 125 023 B1	11/1984	EP	Cabilly, et al.				
	FR	0 125 023 B2	03/2002	EP	Cabilly, et al.				
	GR	0 173 494 A2	03/1986	EP	Morrison, et al.				
	HR	0 274 394 A2	07/1988	EP	Robinson, et al.				
	IR	0 274 394 A3	07/1988	EP	Robinson, et al.				
	JR	0 451 216 B1	01/1996	EP	Queen, et al.				
	KR	0 682 040 A1	11/1995	EP	Queen, et al.				
	LR	0 682 040 B1	11/1995	EP	Queen, et al.				
	MR	WO 88/04936	07/1988	WO	Robinson, et al.				
✓	NR	WO 92/07466	05/1992	WO	Hellström, et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

MS	Adams, R.A. et al., Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, <i>SB-2, Can Res</i> 28:1121-1125 (1968).				
↓	Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, <i>Can. Res.</i> 27:2479-2482 (1967).				
	Anderson, K.C., et al., Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow, <i>Blood</i> 69(2):597-604 (1987)				
	Anderson, D.R., et al., Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody, The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.				
	Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation, <i>Blood</i> 63(6):1424-1433 (1984)				
	Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. <i>Hem. Onc. Clinics of N.A.</i> 5(5):1013-1025 (1991).				
↓	Armitage, J.O. et al., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), <i>Cancer</i> 50:1695 (1982).				
✓	Bhan, A.K., et al., Stages of B cell differentiation in human lymphoid tissue, <i>J. Exp. Med.</i> , 154:737-749 (1981)				


[Handwritten signature]

3/31/2005

01P 135 2003	Boulianne, G.L. <i>et al.</i> , Production of functional chimaeric mouse/human antibody, <i>Nature</i> 312:643 (December 1984).				
2	Brunner, K.T. <i>et al.</i> , Quantitative assay of the lytic action of immune lymphoid cells on ⁵¹ Cr-labeled allogeneic target cells <i>in vitro</i> ; inhibition by isoantibody and drugs, <i>Immunology</i> 14:181-189 (1968).				
TRADEMARK	Buchsbaum, D.J., <i>et al.</i> , A comparison of ¹³¹ I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts, <i>Int. J. Radiation Oncology Biol. Phys.</i> , 18:1033-1041 (1990)				
	Buchsbaum, D.J., <i>et al.</i> , Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies, <i>Cancer Research (Suppl.)</i> 50:993s-999s (1990)				
	Buchsbaum, D.J., <i>et al.</i> , Comparison of ¹³¹ I- and ⁹⁰ Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts, <i>Int. J. Radiation Oncology Biol. Phys.</i> 25:629-638 (1993)				
	Calvert, J.E., <i>et al.</i> , Cellular events in the differentiation of antibody-secreting cells, <i>Seminars in Hematology</i> , 21(4):226-243 (1984)				
	Chomczynski, P. <i>et al.</i> , Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, <i>Anal. Biochem.</i> 162:156-159 (1987).				
	Clark, E.A., <i>et al.</i> , Role of the Bp35 cell surface polypeptide in human B-cell activation, <i>Proc. Natl. Acad. Sci. USA</i> , 82:1766-1770 (1985)				
	Cope, Antibody shows promise in treating B-cell lymphoma, <i>Oncology</i> , 8(4):100 (1994)				
	DeNardo, S.J., <i>et al.</i> , Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1(1):17-33 (1988)				
	DeNardo, S.J., <i>et al.</i> , The biologic window for chimeric L6 radioimmunotherapy, <i>Cancer</i> 73(3):1023-32 (1994)				
	Dickson, Scientists produce chimeric monoclonal abs, <i>Genetic Engineering News</i> 5/3 (March 1985).				
	Eary, J.F. <i>et al.</i> , Imaging and Treatment of B-Cell Lymphoma, <i>J. Nuc. Med.</i> 31/8:1257-1268 (1990).				
	Einfeld, D.A. <i>et al.</i> , Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, <i>EMBO</i> 7:711 (1988)				
	Golay, J.T., <i>et al.</i> , The CD20 (Bp35) antigen is involved in activation of B cells from the G ₀ to the G ₁ phase of the cell cycle, <i>J. Immunology</i> 135(6):3795-3801 (1985)				
	Goldenberg, D.M. <i>et al.</i> , Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, <i>J. Clin. Onc.</i> 9/4:548-564 (1991).				
	Greenberger, J.S., <i>et al.</i> , Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture, <i>Cancer Research</i> 45:758-767 (1985)				
	Hekman, A., <i>et al.</i> , Immunotherapy, The Netherlands Cancer Institute Amsterdam Annual Report, pp. 47-48 (1993)				
	Lipton, J.M., <i>et al.</i> , Distribution of B1, calla, β2 microglobulin and Ia on hematopoietic progenitors and hematopoiesis supporting cells (HSC) in short and long-term cultures, <i>Blood</i> , 60(5) (Suppl. 1):170a (Abstract 609) (1982)				
	Kaminski, M.G. <i>et al.</i> , "Radioimmunotherapy of B-cell lymphoma with [¹³¹ I] anti-B1 (anti-CD20) antibody, <i>NEJM</i> 329/7 (1993).				
	Liu, A.Y. <i>et al.</i> , Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity. <i>J. Immun.</i> 139/10:3521-3526 (1987).				
	Marx, Antibodies made to order, <i>Science</i> 229 455 (August 1985).				
	Morrison, S.L. <i>et al.</i> , Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <i>PNAS</i> 81:6851-6854 (November 1984).				
	Morrison, Transfectomas provide novel chimeric antibodies, <i>Science</i> 229:1202-1207 (September 1985).				
	Munro, Uses of chimaeric antibodies, <i>Nature</i> 312:597 (December 1984).				
	Nadler, L.M., <i>et al.</i> , B cell origin of non-T cell acute lymphoblastic leukemia a model for discrete stages of neoplastic and normal pre-B cell differentiation, <i>J. Clin. Invest.</i> 74:332-340 (1984)				

h l

3/31/2005



		Nadler, L.M., et al., Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma, <i>The Lancet</i> , Vol. II, pp. 427-431 (1984)				
		Nadler, L.M., et al., Serothrapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, <i>Cancer Research</i> , 40:3147-3154 (1980)				
		Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with human physiological effector function, <i>Nature</i> 314:268 (March 1985).				
		Oettgen, H.C., et al., Further biochemical studies of the human B-cell differentiation antigens B1 and B2, <i>Hybridoma</i> , 2(1):17-28 (1983)				
		Ozato, K., et al., Monoclonal antibodies to mouse MHC antigens III. Hybridoma antibodies reacting to antigens to the H-2 ^b haplotype reveal genetic control of isotype expression, <i>J. Immunology</i> , 126(1):317-321 (1981)				
		Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, <i>Blood</i> 69(2):584-591 (1987)				
		Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." <i>New England Journal of Medicine</i> 329/17: 1219-12223 (1993).				
		Press, O.W. et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, <i>J. Clin. Onc.</i> 7/8:1027-1038 (1989)				
		Reff, M., et al., Depletion of a B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>J. Cellular Biochem., Suppl.</i> 17E:260 (Abstract T103) (1993)				
		Reff, M., et al., Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>Blood</i> , 83(2):435-445 (1994)				
		Robertson, M.J., et al., Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia, <i>Blood</i> , 79(9):2229-2236 (1992)				
		Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Hum. Antibod. Hybridomas</i> 2:84-93 (1991).				
		Sahagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, <i>J. Immunol.</i> 137:1066-1074 (1986).				
		Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).				
		Schlom J., et al., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, <i>J. Natl. Cancer Inst.</i> , 82(9):763-771 (1990)				
		Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, <i>Nature</i> 276:269 (1978).				
		Smeland, E.B., et al., Activation of human B cells: Alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells, <i>J. Immunology</i> , 138(10):3179-3184 (1987)				
		Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).				
		Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, <i>Hybridoma</i> 5/1:517 (1986).				
		Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, <i>J. Immunol.</i> 135:8564 (November 1985).				
		Tedder, T.F., et al., The B cell surface molecule B1 is functionally linked with B cell activation and differentiation, <i>J. Immunology</i> , 135(2):973-979 (1985)				
		Urlaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." <i>Som. Cell & Mol. Gen.</i> 12/6:555-566 (1986).				
		Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem.</i> 264(19):11282-11287 (1989).				
		Wessels, B.W., et al., Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies, <i>Med. Phys.</i> , 11(5):638-645 (1984)				

Examiner		Date Considered:	3/31/2005
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>			